30 March -1 April 2020 | Business Design Centre London



1-2-1 Meetings




IMMUNOTHERAPY, Tuesday 31 March 2020

CONFERENCE DAY 1 - TUESDAY 31st March 2020

Opening Keynotes Day 1 – CAR-T & Immunotherapy focus

Prasad Adusumilli

Keynote presentaton: Autologous Mesothelin-targeting CAR-T to tackle solid tumours in the clinic

  • The presentation will highlight results to date of mesothelin-targeted CAR T-cell clinical trial results
  • Advances in preclinical research of CAR T-cell therapy for solid tumors will be presented
  • Novel strategies for overcoming hurdles to solid tumor CAR T-cell therapy will be discussed
Panel discussion

Realizing the promise of ATMPs for patients around the world

  • Working with regulators to navigate scale up challenges in manufacturing
  • Strategies in supply chain and patient delivery
  • Tackling post manufacturing commercialization challenges such as pricing and finding highly skilled experts
  • Durability

Morning Coffee Break

Mark Sawicki

Effective Integration Strategies Through a Compliance Unified Ecosystem (CUE)

  • Systems Integration continues to be a major issue in the production and distribution of Advanced Therapies
  • Well-defined strategies for the integration of independent informatics platforms will be critical for future standardization and workflow optimization
  • Cryoport’s Compliance Unified Ecosystem (CUE) is driving standard practices for systems integration in the industry
round tables

Technology and Strategy Roundtables will run from 12:00-12:45 with 15 minutes for a quick summary from each table at the front of the room. These will take place in the conference rooms: look for you

Technology and Strategy Roundtables will run from 12:00-12:45 with 15 minutes for a quick summary from each table at the front of the room. These will take place in the conference rooms: look for your table number to participate.
1. Raw material supply for the commercial manufacturing of cell and gene therapies
Frank Hecht

Frank Hecht, Vice President Marketing And Sales, CellGenix GmbH

11. Cord blood as a source of new cells
12. Tissue engineering for organ regeneration
Vaidehi Joshi

Vaidehi Joshi, Scientist II, Therapeutics, Organovo

13. TBC
14. Making allogeneic cell therapy a reality
Devyn Smith

Devyn Smith, Chief Operating Officer And Head Of Strategy, Sigilon

15. Industry-no profit alliances: how to optimize synergies
Elena Beltrami

Elena Beltrami, Business Development Manager, Fondazione Telethon

17. How companies can interact with the regulator and various pitfalls to be aware of
John Johnston

John Johnston, Clinical Assessor, Medicines & Healthcare Products Regulatory Agency

18. Ensuring ATMP access to patients
Delphine Roulland

Delphine Roulland, Director Government Affairs And Public Policy, European Confederation of Pharmaceutical Entrepreneurs (Belgium)

19. Roundtable available
2. Physiological conditions and analytical and monitoring tools for 3D cell cultivations
Cornelia Kasper

Cornelia Kasper, Professor, Biopharmaceutical Production And Technology, B.O.K.U.

21. Neurological applications for ATMPs
22. Development of regenerative medicines for cardiovascular indications
David Mazzo

David Mazzo, Chief Executive Officer, Caladrius Biosciences

23. Renal applications for ATMPs
24. Tackling diabetes with ATMPs
3. TBC (Reserved for Schott)
Sebastian Kress

Sebastian Kress, Post Doc, BOKU

5. Considerations for manufacture scale-up from academia to commercial manufacturing
Johannes Van Der Loo

Johannes Van Der Loo, Clinical Vector Core Director, The Children's Hospital of Philadelphia

9. Exploring the crossover between human and veterinary applications for stem cells
Joanna Miller

Joanna Miller, Chief Scientific Officer, Cell Therapy Sciences



Dr Roy Baynes

PD-1 antibodies are transforming cancer therapy both as mono- and in combination

  • PD-1 antibody activity in monotherapy may be enriched with precision medicine tools.
  • Precision medicine may help define resistance biology and enable rational combinations.
  • Certain combinations (e.g. chemotherapy or TKIs + PD-1 antibodies) may be broadly active without regard for biomarker-based selection.
Igor Rudychev

From big patient-level data to actionable insights and answering right business questions in oncology

  • How Patient-Level data can help us to solve business questions from Advanced Therapies
  • Oncology case studies
  • How to optimize the business with data driven insights
Cynthia Bamdad

1st-in-Human CAR T Targets MUC1 Cleavage Product Expressed on Solid Tumors

  • 1st-in-Human Trial for metastatic breast cancer open at the Fred Hutchinson Cancer Research Center.
  • huMNC2-CAR44 recognizes a cancer-specific MUC1 cleavage product called MUC1* (muk 1 star).
  • Antibody huMNC2 recognizes a conformational epitope formed when MUC1 is cleaved to MUC1* by an enzyme that is overexpressed in most solid tumors
Giuseppe Mazza

Engineered tumor micro-environment using human extracellular matrix for modelling hot and cold tumours.

Hans S Keirstead

Clinical application of scaled human stem cell derivates in immune-oncology


Afternoon Break

Panel discussion

Panel discussion: Precision medicine for immunotherapy

  • Using biomarkers and diagnostics to start correlating success rates in immunotherapy: how to know when to apply these
  • Which is more important: stratification of patients using biomarkers or identifying the correct cells for a specific application?
  • Gene editing therapeutics

Close of Conference for the day - Please join us for an evening drinks reception at the iconic Emirates Stadium

last published: 28/Jan/20 14:05

IMMUNOTHERAPY, Wednesday 1 April 2020


Opening Remarks

Federico Mingozzi

Gene therapy 2.0: New clinical data, therapeutic applications and next generation technologies

  • Latest updates on LUXTURNA studies to treat blindness, haemophilia and rare disease
  • Tackling the challenges of viral gene therapies i.e. immunogenicity
  • Developing the next generation of gene therapies, what does the future hold?
Steve Kanner

Next-generation gene editing technology for allogeneic immune cell therapeutics

  • Next-generation CRISPR-Cas9 technology
  • Significantly enhanced editing specificity
  • Editing in immune cells for generation of functionally tuned therapeutics
Adrian Woolfson

Repairing the human genome with designed zinc finger editing reagents

  • Overview of Sangamo’s zinc finger protein gene editing technology, including new innovations that facilitate specificity, precision, and gene editing efficiency
  • Will address specific examples of defined therapeutic applications including the generation of reagents suitable for use in tauopathies, Huntington’s disease, and lysosomal storage diseases
Frederic Chereau

In vivo gene editing paediatric patients with rare diseases


Networking Refreshments


Immuno-oncology for breast cancer

David Pauza

At the intersection of genetic medicine and immunotherapy: Clinical experience with a cell and gene therapy for HIV disease


Neworking Lunch

David Blakey

Small activating RNAs as a novel approach for immunotherapy

  • Small activating RNAs can be designed to a wide range of targets to activate gene transcription
  • MiNA Therapeutics’lead saRNA to CEBPA has demonstrated proofof concept in the clinic
  • Novel saRNAs have been designed to specifically up-regulated immune targets for cancer immunotherapy

Gene modified Cell Therapy: Gene modified T-Cells for solid tumours


Networking refreshments

last published: 28/Jan/20 14:05